4.16.23
All news and presentations
Read More
4.16.23
Accent Presents: "Targeting DHX9 Inhibition as a Novel Therapeutic Modality in Microsatellite Instable Colorectal Cancer" (AACR 2023)
4.6.23
Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023
3.2.23
Accent Presents: “Discovery of Small Molecule Inhibitors of ADAR1” (GRC 2023) Poster
3.2.23
Accent Presents: “Development of Assays to Support Identification and Characterization of Modulators of DEAH-Box Helicase DHX9” (SLAS2023)
10.18.21
Ipsen Adds Another Program Into Its Pre-clinical R&D; Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, Mettl3
6.4.2020
Accent Therapeutics and Astrazeneca to Discover and Develop Novel Cancer Therapeutics in New Collaboration
4.23.2020
Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting Rna-modifying Proteins
9.3.2019
Accent Therapeutics Appoints Shakti Narayan as Chief Executive Officer
5.18.2018